Citius Pharmaceuticals, Inc. (CTXR) Form 8-K — Aug 14, 2026
Citius Pharmaceuticals reported fiscal third quarter 2026 results on August 14, 2026, with LYMPHIR delivering its first commercial revenue: $1.5 million for the quarter ended June 30, 2026 and $7.1 million for the first nine months of fiscal 2026, compared with no revenue in the prior-year periods. Management said the launch gained momentum, with LYMPHIR now available at 44 institutions and July institutional orders of 383 vials marking the largest month to date.
Key figures
- Revenue
- 1493788
- Total Debt
- 6410161
- Total Assets
- 142255198
- Cash Position
- 17007523
- Shares Outstanding
- 27452570
- Gross margin q3
- approximately 67%
- Gross profit q3
- 1001945
- Pre cart dlbcl cr
- 57%
- Pre cart dlbcl orr
- 86%
- Revenue nine months
- 7105197
- Revenue prior year q3
- 0
- Term loan facility max
- 25000000
- Pembrolizumab combo orr
- 24%
- Vials ordered july 2026
- 383
- Gross margin nine months
- approximately 77%
- Institutions with lymphir
- 44
- Ownership of citius oncology
- approximately 62%
- Warrant exercise net proceeds
- approximately $9.7 million
- Term loan first tranche funded
- 10000000
- Institutional vial order growth
- 31%
- Lymphir initial market estimate
- >$400 million
- New institutions ordering growth
- 80%
- Contract cancellation charge march 2026
- $19.7 million (non-recurring)
- Commercial and medical affairs headcount
- 29
- Registered direct offering net proceeds april 2026
- approximately $4.5 million
Price after filing
1 day: 0.0%7 days: -20.6%30 days: -23.1%
Close on the filing date to close N calendar days later (from $0.76). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.